IsoRay's Cesium-131 Therapy Stops Brain Cancers from Recurring in Treated Locations Where Previous Conventional Treatments Failed

World-Renowned Barrow Neurological Institute Releases Dramatic Brain Study Findings

RICHLAND, WA December 1, 2014 / IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced the striking results of a study of brain cancer patients treated with IsoRay’s Cesium-131 internal radiation (brachytherapy) cancer therapy. The findings of the study, conducted by researchers at Barrow Neurological Institute, were presented at the November 2014 annual meeting of the Society for Neuro-Oncology in Miami, Florida.

Can-Fite Reports Financial Results for Nine Months Ended September 30, 2014

PETACH TIKVA, Israel, Dec. 1, 2014 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported financial results for the nine months ended September 30, 2014 and updates on its clinical programs.

Clinical and Corporate Highlights Include:

• CF101 – Data release from the Psoriasis Phase II/III study
  Can-Fite has completed enrollment of over 300 patients at 17 clinical centers in the U.S., Europe, and Israel in its Phase II/III trial for the treatment of psoriasis. Top line results from the trial are expected in the first quarter of 2015. Can-Fite has already received positive interim data from the first 100 patients. In addition, Can-Fite is planning a Phase III trial for rheumatoid arthritis based on the positive data of its Phase II study. Data from the Phase II ongoing glaucoma study (aimed at 88 patients) is expected to be released in Q2/Q3 2015.

Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer

CAMBRIDGE, Mass., Dec. 1, 2014 -- Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of necuparanib, the Company's novel oncology drug candidate, as a first-line treatment in combination with Abraxane^(R) and gemcitabine in patients with metastatic pancreatic cancer. Momenta recently announced the successful completion of Part A of the Phase 1/2 study and has initiated the Part B (Phase 2 proof-of-concept) study.

Synthetic Biologics Safe-to-Proceed Under IND to Initiate Clinical Trials of SYN-004 for the Prevention C. difficile Infection

-- Phase 1a and 1b Trials to Use SYN-004 to Protect Microbiome; Intended to Prevent Overgrowth of Potentially Deadly C. difficile Bacteria --

ROCKVILLE, Md., Nov. 24, 2014 -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that its Investigational New Drug (IND) application which was submitted to the U.S. Food and Drug Administration (FDA) in October will be proceeding into clinical trials for the development of the Company's oral beta-lactamase enzyme SYN-004 for the prevention of Clostridium difficile (C. difficile) infection (CDI), antibiotic-associated diarrhea (AAD) and secondary infections with healthcare-acquired, drug-resistant pathogens in patients receiving intravenous (IV) beta-lactam antibiotic therapy. Synthetic Biologics plans to begin Phase 1a and 1b clinical trials shortly, with topline data expected to be reported before year-end.